RespireRx Pharmaceuticals Inc (RSPI)

[drfreely]

You're absolutely right. Biotech, particularly the neuro end of the business, is now operating under the "golden rule." Those with the gold, rule.
While our pipe line is more robust than in the past, all we've had to show for our efforts is one Proof of Concept trial sold out with no back end: RD.
We've never run an FDA trial. We almost ran one.
Big pharmas are looking for items further along that ours that can fill a niche that's going generic in the forseeable future.
So, although it pains the Longs and Varney, not sure enough of what's out there can be licensed out to raise the 20 plus million needed to run ADHD, and keep independence.